Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years (male or female)~2. Acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)~3. Currently admitted to an intensive care unit (ICU)~Key Exclusion Criteria:~1. Ongoing (\>48 hours) or planned full-dose (therapeutic) anticoagulation for any indication~2. Ongoing or planned treatment with dual antiplatelet therapy~3. Contraindication to antithrombotic therapy or high risk of bleeding due to conditions including, but not limited to, any of the following:~   1. History of intracranial hemorrhage, known central nervous system (CNS) tumor or CNS vascular abnormality~  2. Active or recent major bleeding within the past 30 days with untreated source~  3. Platelet count \<70,000 or known functional platelet disorder~  4. Fibrinogen \<200 mg/dL~  5. International normalized ratio (INR) \>1.9~4. History of heparin-induced thrombocytopenia~5. Ischemic stroke within the past 2 weeks~Patients who meet the following criterion are excluded from the second randomization (antiplatelet therapy vs. no antiplatelet therapy):~1. Ongoing or planned antiplatelet therapy, including aspirin monotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full-dose anticoagulation (FDAC) (Type: EXPERIMENTAL): * Unfractionated heparin (UFH) administered intravenously with a nomogram targeting an activated partial thromboplastin time (aPTT) of 1.5-2.5 times the control as per institutional therapeutic target for treatment of venous thrombotic events (VTE)~* Enoxaparin 1 mg/kg administered subcutaneously (SC) every 12 hours~* With or without anti-platelet therapy: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily on subsequent days
- Standard-dose prophylactic anticoagulation (SDPAC) (Type: ACTIVE_COMPARATOR): * Enoxaparin 40 mg administered subcutaneously (SC) once daily (reduce to 30 mg if creatinine clearance CrCl \<30 ml/min)~* Heparin 5,000 units administered subcutaneous three times daily~* With or without anti-platelet therapy: Clopidogrel 300 mg administered once orally on the day of randomization, followed by 75 mg administered once daily on subsequent days

Based on this trial design, predict the completion outcome and termination type (if applicable).